A phase 1, open-label, dose-escalation study of SGN-CD19B in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma

Type of Cancer
Lymphoma

Phase

Division (Location)

Study ID

NCT#

Brief Description
A phase 1, open-label, dose-escalation study of SGN-CD19B in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma

To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.